1. Home
  2. PGEN vs GNFT Comparison

PGEN vs GNFT Comparison

Compare PGEN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • GNFT
  • Stock Information
  • Founded
  • PGEN 1998
  • GNFT 1999
  • Country
  • PGEN United States
  • GNFT France
  • Employees
  • PGEN N/A
  • GNFT N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PGEN Health Care
  • GNFT Health Care
  • Exchange
  • PGEN Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • PGEN 292.6M
  • GNFT 190.6M
  • IPO Year
  • PGEN N/A
  • GNFT 2019
  • Fundamental
  • Price
  • PGEN $0.74
  • GNFT $3.75
  • Analyst Decision
  • PGEN Buy
  • GNFT Strong Buy
  • Analyst Count
  • PGEN 5
  • GNFT 1
  • Target Price
  • PGEN $7.00
  • GNFT $13.00
  • AVG Volume (30 Days)
  • PGEN 1.1M
  • GNFT 8.9K
  • Earning Date
  • PGEN 11-14-2024
  • GNFT 09-19-2024
  • Dividend Yield
  • PGEN N/A
  • GNFT N/A
  • EPS Growth
  • PGEN N/A
  • GNFT N/A
  • EPS
  • PGEN N/A
  • GNFT 0.47
  • Revenue
  • PGEN $3,963,000.00
  • GNFT $86,225,222.00
  • Revenue This Year
  • PGEN N/A
  • GNFT $155.44
  • Revenue Next Year
  • PGEN $402.12
  • GNFT N/A
  • P/E Ratio
  • PGEN N/A
  • GNFT $7.55
  • Revenue Growth
  • PGEN N/A
  • GNFT 175.45
  • 52 Week Low
  • PGEN $0.65
  • GNFT $3.31
  • 52 Week High
  • PGEN $1.93
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 46.11
  • GNFT 29.68
  • Support Level
  • PGEN $0.71
  • GNFT $3.63
  • Resistance Level
  • PGEN $0.78
  • GNFT $3.94
  • Average True Range (ATR)
  • PGEN 0.05
  • GNFT 0.12
  • MACD
  • PGEN 0.01
  • GNFT 0.03
  • Stochastic Oscillator
  • PGEN 61.00
  • GNFT 0.69

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: